Early and late tamoxifen resistance in breast cancer | Zendy

Rabi Abu | Zendy; Milan Markićević | Zendy; Tijana Vujasinović | Zendy; Silvana Lukić | Zendy; Ljiljana Stamatović | Zendy; Dragica NikolićVukosavljević | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Early and late tamoxifen resistance in breast cancer

Author(s) -

Rabi Abu,

Milan Markićević,

Tijana Vujasinović,

Silvana Lukić,

Ljiljana Stamatović,

Dragica NikolićVukosavljević

Publication year - 2010

Publication title -

archives of biological sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.217

H-Index - 25

eISSN - 1821-4339

pISSN - 0354-4664

DOI - 10.2298/abs1002249a

Subject(s) - tamoxifen , breast cancer , estrogen receptor , oncology , medicine , oestrogen receptor , estrogen , progesterone receptor , disease , cancer , gynecology

In our study we investigated the role of the estrogen receptor (ER), progesterone receptor (PR) and clinicohistological parameters in breast cancer patients treated with tamoxifen during the early (2.5 years) vs. late (2.5-5 years) follow-up. The negative status of both ER and PR and tumors equal to or bigger than 2 cm defined the phenotypes and consequently the groups of patients with the worst clinical course of the disease: ER-negative PR-negative, ER-negative pT2 and PR-negative pT2. These high-risk subgroups were related to early follow-up indicating de novo resistance. It is relevant to point out that examined predictive indicators did not show significant importance in the late follow-up study

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research